The present invention is related to a composition intended for the treatment of Parkinson disease which comprises levodopa, carbidopa, entacapone or pharmaceutically acceptable salts, solvates or hydrates of these molecules in a combined form. The invention is characterized in that it comprises both levodopa and carbidopa as extended release form and entacapon as immediately release form.